Αποτελέσματα Αναζήτησης
In this 12-week clinical trial, brexpiprazole, 2 or 3 mg, showed a statistically significant improvement vs placebo on agitation in patients with Alzheimer dementia. Brexpiprazole was generally well tolerated over 12 weeks in this vulnerable patient population.
27 Ιουν 2024 · Rexulti was the first medicine approved by the FDA for reducing symptoms of agitation in dementia due to Alzheimer’s disease. How Does the Medicine Work?
18 Μαΐ 2023 · Rexulti (brexpiprazole) is an approved once-daily oral therapy for reducing agitation associated with dementia due to Alzheimer’s disease.
Yet the US Food and Drug Administration (FDA) has fast tracked its approval, making Rexulti the first antipsychotic for treating agitation in elderly patients with dementia. At a cost of around $1,400 a month Rexulti’s makers, Otsuka and Lundbeck, are forecasting an additional $1 billion in annual sales, but there are serious questions about ...
31 Ιουλ 2024 · New analysis from an extension trial confirmed the efficacy of REXULTI in treating patients with agitation associated with dementia due to Alzheimer's disease. The analysis explored clinically meaningful response (CMR) among patients over 12 and 24 weeks (NCT03548584 and NCT03594123), defined by a 20-point score reduction from baseline in Cohen ...
12 Μαΐ 2023 · The U.S. Food and Drug Administration (FDA) this week approved the expanded use of Rexulti (brexpiprazole) for the treatment of agitation associated with dementia due to Alzheimer’s disease (AD).
11 Μαΐ 2023 · Today, the U.S. Food and Drug Administration is announcing the supplemental approval of Rexulti (brexpiprazole) oral tablets for the treatment of agitation associated with dementia due to...
